Abstract:
Baicalin is a biologically active flavonoid compound that benefits the organism in various pathological conditions. Rodent studies have shown that this compound effectively alleviates diabetes-related disturbances in models of type 1 and type 2 diabetes. Baicalin supplementation limited hyperglycemia and improved insulin sensitivity. The anti-diabetic effects of baicalin covered the main insulin-sensitive tissues, i.e., the skeletal muscle, the adipose tissue, and the liver. In the muscle tissue, baicalin limited lipid accumulation and improved glucose transport. Baicalin therapy was associated with diminished adipose tissue content and increased mitochondrial biogenesis. Hepatic lipid accumulation and glucose output were also decreased as a result of baicalin supplementation. The molecular mechanism of the anti-diabetic action of this compound is pleiotropic and is associated with changes in the expression/action of pivotal enzymes and signaling molecules. Baicalin positively affected, among others, the tissue insulin receptor, glucose transporter, AMP-activated protein kinase, protein kinase B, carnitine palmitoyltransferase, acetyl-CoA carboxylase, and fatty acid synthase. Moreover, this compound ameliorated diabetes-related oxidative and inflammatory stress and reduced epigenetic modifications. Importantly, baicalin supplementation at the effective doses did not induce any side effects. Results of rodent studies imply that baicalin may be tested as an anti-diabetic agent in humans.
摘要:
黄芩苷是一种生物活性类黄酮化合物,在各种病理条件下对生物体有益。啮齿动物研究表明,该化合物可有效缓解1型和2型糖尿病模型中与糖尿病相关的紊乱。补充黄芩苷限制高血糖并改善胰岛素敏感性。黄芩苷的抗糖尿病作用覆盖了主要的胰岛素敏感组织,即,骨骼肌,脂肪组织,还有肝脏.在肌肉组织中,黄芩苷限制脂质积累和改善葡萄糖转运。黄芩苷治疗与脂肪组织含量减少和线粒体生物发生增加有关。补充黄芩苷也降低了肝脏脂质积累和葡萄糖输出。该化合物的抗糖尿病作用的分子机制是多效性的,并且与关键酶和信号分子的表达/作用的变化有关。黄芩苷积极影响,其中,组织胰岛素受体,葡萄糖转运蛋白,AMP激活的蛋白激酶,蛋白激酶B,肉碱棕榈酰转移酶,乙酰辅酶A羧化酶,和脂肪酸合成酶.此外,该化合物改善了糖尿病相关的氧化和炎症应激,并减少了表观遗传修饰.重要的是,有效剂量的黄芩苷补充没有引起任何副作用。啮齿动物研究的结果表明,黄芩苷可以作为抗糖尿病剂在人体中进行测试。